Search Results
642 results
Your search is now limited to «Pfizer» expert search.
GlobeNewswire 01/16/2019 12:47
WATERTOWN, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that the first patient has been enrolled in a Phase 2a expansion cohort intended to assess preliminary activity and safety of ALRN-6924 in combination with Pfizer’s palbociclib, also known as IBRANCE®, in cancer patients with MDM2-amplified solid tumors.
More from GlobeNewswire:
Seeking Alpha 01/16/2019 11:48
Benjamin Graham On Jan. 10, 2019, the shares of Amarin Corporation (AMRN) rallied over 22% due to the news that Pfizer (PFE) is interested in buying out the company.
More from Seeking Alpha:
FiercePharmaManufacturing 01/16/2019 11:42
Pfizer will transfer technology that will permit Medochemie to manufacture 11 of Pfizer’s products, including four sterile injectables and seven tablets.
More from FiercePharmaManufacturing: 01/16/2019 10:22
Janssen's Stelara and Pfizer's Xeljanz Battle Takeda's Entyvio to Claim the Preferred Alternate Mechanism of Action... Spherix Global Insights ......
More from
ENDPOINTS 01/16/2019 07:14
The checkpoint frenzy in the immuno-oncology sphere has largely focused on blocking the ligand-receptor duo of PD-L1 and PD-1, which cancer cells use to shield themselves from the immune system. Dissatisfied by the ability of PD-L1 agents to go after aggressive, metastatic cancers, a group of UCSF researchers are charting a new path: What if the production of checkpoint proteins could be stopped from the outset? Davide Ruggero. In a mice trial, the researchers found that they could pull back the “robust PD-L1 invisibility cloak” used by cancer cells, increasing survival rates by disrupting the translation of RNA into proteins — using a molecule developed by eFFECTOR Therapeutics, a biotech co-founded by the study’s senior author Davide Rugge.
More from ENDPOINTS:
PR Newswire 01/16/2019 07:00
Brand share follows the same pattern, with Pfizer's JAK capturing nearly three times more of the US market than what is reported across the EU5.
More from PR Newswire:
(MENAFN - GetNews) Global Bipolar Disorder Treatment Industry 2018 Market Research Report has been analyzed in detail to assist clients with all the vital data to frame tactical bu...
More from Middle East North Africa Financial Network (MENAFN):
BioPharma Dive 01/15/2019 10:00
The new House Oversight chairman has asked 12 pharmas for pricing info on 18 top drugs, as Congress prepares to further scrutinize the industry.
More from BioPharma Dive:
pharmaphorum 01/15/2019 04:14
He would also not be drawn on Pfizer’s pricing plans for the drug, saying merely that Pfizer prices all its drugs “compared to the value that they bring to the healthcare system.
More from pharmaphorum:
Pfizer’s tafamidis meglumine form (20mg capsule) has secured priority review from the US Food and Drug Administration (FDA) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM.
More from Pharmaceutical Business Review:
MarketWatch 01/14/2019 08:56
Pfizer submitted the NDAs based on two forms of the drug for treatment of transthyretin amyloid cardiomyopathy, a fatal condition where a transport protein in the blood misfolds and results in a build-up of amyloid ...
More from MarketWatch:
Industrial Info 01/14/2019 02:11
GALWAY, IRELAND--January 14, 2018--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--GlaxoSmithKline (NYSE:GSK) (GSK) (Brentford, England) and Pfizer (NYSE:PFE) (New York, New York) have announced plans to merge their consumer healthcare divisions with combined sales of approximately £9.8 billion ($12.7 billion). Within this article: Details proposed merger, value, product lines affected, impact on manufacturing and jobs.
Business Standard (India) 01/13/2019 12:54
Pfizer offers severance package to employees of Chennai, Aurangabad units.
More from Business Standard (India):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications